Eli Lilly to acquire Sigilon Therapeutics in a deal worth over $300 million
29/06/2023 11:59
June 29 (Reuters) - Eli Lilly and Co LLY.N said on Thursday it would acquire Sigilon Therapeutics Inc SGTX.O in an all-cash deal that could be worth more than $300 million, excluding shares held by Lilly. (Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Sigilon Therapeutics
See all newsSigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Sigilon Therapeutics Inc expected to post a loss of $4.71 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Sigilon jumps on Eli Lilly's buyout deal to expand diabetes treatments
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx